PRODUCT TYPES – Page 33

Radiochemical purity OOS during radiopharma production: regulatory deviation handling

The first step in managing an OOS event related to radiochemical purity is recognizing the signals that indicate a problem. Symptoms may include:Click to read the full article.

Biosimilar immunogenicity risk signal after downstream resin change: bridging study planning and regulatory communication strategy

Identifying the right symptoms is fundamental in any investigation. In the case of immunogenicity following a change in downstream resin, common signals might include:Click to read the full article.

Microbial limits failure during regulatory submission: risk assessment for animal and food safety

Microbial limits failures often manifest through various signals that can appear in manufacturing or laboratory settings:Click to read the full article.

Radiochemical purity OOS during transport to clinic: patient safety assessment

Investigating Radiochemical Purity OOS During Transport to Clinic: A Comprehensive Approach Ensuring the radiochemical purity of radiopharmaceuticals during transport to clinics is critical for patient safety and regulatory compliance. Out-of-Specification…

Analytical similarity failure (Tier 1 CQAs) during FDA/EMA scientific advice / meetings: FDA/EMA expectations for root cause, rework, and comparability justification

Symptoms of analytical similarity failure may first become apparent through various signals during routine quality control or during stability studies. Recognizing these symptoms early is critical. Common symptoms include:Click to…

Assay OOS during regulatory submission: GMP investigation and CAPA

Investigation of Assay OOS Results during Regulatory Submission: A GMP Approach In the rigorous landscape of pharmaceutical manufacturing, encountering out-of-specification (OOS) assay results during regulatory submission can trigger significant repercussions.…

Half-life deviation during transport to clinic: patient safety assessment

Identifying symptoms signifying a half-life deviation is crucial in preventing further complications. Common signals encountered in a laboratory or manufacturing environment may include:Click to read the full article.

Biosimilar lot-to-lot variability trend (OOT) after cell line or upstream change: FDA/EMA expectations for root cause, rework, and comparability justification

Recognizing symptoms early in the manufacturing process is crucial to address lot-to-lot variability effectively. Common signals may include:Click to read the full article.

Labeling deviation during stability studies: regulatory communication strategy

Detecting symptoms of a labeling deviation early is essential to prevent escalation. Common signals include:Click to read the full article.

Radiochemical purity OOS during dispensing: CAPA under time-critical constraints

Radiochemical purity OOS incidents often present themselves through various signals during the dispensing phase. Recognizing these symptoms early can help mitigate risk and initiate a timely investigation. Common symptoms workers…

Biosimilar charge variant profile drift during FDA/EMA scientific advice / meetings: how to build a defensible similarity narrative with data integrity controls

In the context of biosimilar production, charge variant profile drift can manifest through a variety of signals, which should be systematically monitored to ensure product quality and regulatory compliance. Notable…

Assay OOS in veterinary product manufacturing: regulatory communication strategy

Identifying the right signals that indicate an Assay OOS is critical for timely intervention. Common symptoms observed on the shop floor or in the laboratory include:Click to read the full…